Reported positive (1)
- Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Meta-analysis · Moderate evidence · Apr 2024
Durvalumab
Evidence at a glanceHuman trial / meta-analysisMixed results⚠ Studies disagree
4 published studies tagged to this agent2 human studies approved & graded (trial, observational, or meta-analysis)
Why this grade?
Human trial / meta-analysis — Includes human trial or meta-analysis evidence.
- 2 human · 0 animal · 0 lab · 2 review/other
- Most authoritative study: Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
- Studies disagree on the reported direction (conflict flagged).
- Findings conflict across studies
- Effect sizes reported in only 3 of 4 studies
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curateddurvalumab
Educational only, not medical advice. OncoForge makes no claim that Durvalumab treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
CancerHuman evidenceMechanismSafetyTrial
Endometrial Carcinosarcoma22—2
- Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis Meta-analysisReported positive
- Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study Human trialReported negative
Advanced Endometrial Cancer11—1
Endometrial Cancer11—1
Endometrial Carcinoma11—1
Recurrent Endometrial Cancer11—1
Extrapulmonary Small Cell Carcinoma (Epscc) Of The Prostate————
Extrapulmonary Small Cell Carcinoma Of The Liver————
- Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab Case reportMixed results
Metastatic Prostate Cancer————
Prostate Adenocarcinoma————
Reported figures
Study mix
4 published studies by what they were done in. Lab and animal findings often do not carry over to people.
2 Human2 Review/other
Reported directionReported positive1Mixed results1Reported negative1Inconclusive1
What supports this page
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Guideline0
Meta-analysis1
Systematic review0
Randomized trial0
Clinical trial1
Observational0
Case report2
Review0
Preclinical0
Other0
4 studies2 human2 review/other
Tracking 4 published studies of Durvalumab: 2 in humans, 2 reviews/other.
Reported direction across studies: 1 positive, 1 mixed, 1 negative, 1 inconclusive.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.
These counts summarize what the studies reported; they are not a measure of whether Durvalumab works.
Cancers named in these studies
endometrial carcinosarcoma (2)extrapulmonary small cell carcinoma of the liver (1)advanced endometrial cancer (1)recurrent endometrial cancer (1)extrapulmonary small cell carcinoma (EPSCC) of the prostate (1)prostate adenocarcinoma (1)metastatic prostate cancer (1)endometrial cancer (1)endometrial carcinoma (1)
Conflicting evidence
Negative or mixed (2)
- Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab
Case report · Limited evidence · Mar 2025 - Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
Human trial · Limited evidence · Feb 2023
All studies
Case reportMixed resultsLimited evidenceTier 3 · early humann = 1
Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab
Radiology case reports · Mar 2025 · case report
This is a single-patient case report of extrapulmonary small cell carcinoma of the liver in a 52-year-old woman. The patient received systemic chemotherapy with carboplatin and etoposide combined with durvalumab, had clinical improvement of symptoms, but died 10 months after starting chemoimmunotherapy. The authors note that optimal treatment for EPSCC is generally extrapolated from small cell lung cancer and that there is insufficient evidence to routinely recommend immunotherapy in this group.
Reported effects: tumor_dimensions, n=1 · time_to_death_after_starting_chemoimmunotherapy 10 mo, n=1
Studied with: carboplatin, etoposide, carboplatin + etoposide.
Key findings
- Diagnosis of EPSCC of the liver was made after biopsy and immunohistochemistry (positive for CKA1/A3, chromogranin, synaptophysin, CD56 and TTF-1).
- Abdominal MRI showed an enlarged liver secondary to a mass affecting segments IV, V, VI, VII and VIII of 16.9 × 9.4 cm.
- Systemic chemotherapy with carboplatin and etoposide plus durvalumab was started.
- There was clinical improvement of the symptoms after starting treatment.
- The patient died 10 months after starting chemoimmunotherapy treatment.
- Authors state that optimal treatment of EPSCC is generally extrapolated from small cell lung cancer and there is insufficient evidence to routinely recommend immunotherapy for EPSCC.
Limitations: Single-patient case report (n=1), so findings are not generalizable.; No control or comparator group to assess treatment effect.; No dosing, schedule, or detailed treatment toxicity information provided.; Cannot establish causality or efficacy from a single observational case.; EPSCC is rare and treatment recommendations are extrapolated from small cell lung cancer, limiting direct applicability..
This report describes use of carboplatin + etoposide chemotherapy combined with durvalumab in a patient with extrapulmonary small cell carcinoma of the liver.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Meta-analysisTrialReported positiveModerate evidenceTier 4 · clinicaln = 2456
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Cancer treatment reviews · Apr 2024 · meta-analysis of randomized controlled trials (first-line ICI + platinum-based chemotherapy vs chemotherapy alone)
AtezolizumabAvelumabDurvalumabDostarlimabPembrolizumabadvanced endometrial cancerrecurrent endometrial cancerendometrial carcinosarcoma
This meta-analysis pooled five randomized trials (2456 patients) comparing addition of anti-PD-1 or anti-PD-L1 agents to standard platinum-based chemotherapy versus chemotherapy alone as first-line treatment for advanced or recurrent endometrial cancer. Adding immune checkpoint inhibitors improved progression-free survival overall and especially in tumors with deficient mismatch repair (dMMR); in mismatch repair–proficient (pMMR) tumors a statistically significant PFS benefit was reported only with anti-PD-1 agents, not anti-PD-L1 agents. The analysis reports PFS outcomes; the impact on overall survival remains to be clarified.
Reported effects: included patients 2456, n=2456 · pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 · +5 more
Studied with: carboplatin-paclitaxel chemotherapy.
Key findings
- Five randomized trials comprising 2456 patients (1308 received ICIs + chemotherapy and 1148 chemotherapy alone) were included.
- Addition of ICIs to chemotherapy improved PFS in the overall population (pooled HR, 0.63; 95% CI, 0.52–0.76; P < .001).
- In the dMMR subgroup the pooled PFS benefit was larger (pooled HR, 0.34; 95% CI, 0.27–0.44; P < .001).
- In dMMR tumors benefit was seen with both PD-L1 and PD-1 inhibitors (pooled HRs 0.39, 95% CI 0.28–0.55 and 0.34, 95% CI 0.27–0.44, respectively; both P < .001).
- In pMMR patients a statistically significant PFS benefit was observed only with anti-PD-1 agents (anti-PD-1: HR 0.64, 95% CI 0.46–0.90, P = .010) but not with anti-PD-L1 agents (anti-PD-L1: HR 0.87, 95% CI 0.73–1.03, P = .104).
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
Case reportInconclusiveLimited evidenceTier 3 · early humann = 1
Managing a Rare Case of Mixed Extrapulmonary Small Cell Carcinoma and Adenocarcinoma of the Prostate
Cureus · Jun 2023 · case report
CarboplatinEtoposideDurvalumabextrapulmonary small cell carcinoma (EPSCC) of the prostateprostate adenocarcinomametastatic prostate cancer
This is a single-patient case report of a 77-year-old man with prior prostate adenocarcinoma who developed extrapulmonary small cell carcinoma of the prostate. The patient did not improve with bicalutamide and leuprorelin, and clinicians administered carboplatin-etoposide chemotherapy with durvalumab based on treatments used for small cell lung cancer. The authors state that EPSCC of the prostate is aggressive, lacks established treatment protocols, and call for further research and clinical trials.
Studied with: bicalutamide + leuprorelin, carboplatin + etoposide, durvalumab (given with carboplatin-etoposide).
Key findings
- Extrapulmonary small cell carcinoma (EPSCC) in the prostate is an aggressive and rare malignancy with unfavorable survival outcomes (reported as a general statement).
- The reported patient did not show improvement after standard therapy with bicalutamide and leuprorelin.
- The treating team administered a carboplatin-etoposide chemotherapy regimen together with durvalumab, extrapolating from small cell lung cancer approaches.
- The authors highlight a lack of established treatment protocols for prostate EPSCC and the need for further research and clinical trials.
Limitations: Single-patient case report (n=1), so findings are not generalizable.; Abstract does not report objective outcomes or follow-up after administration of carboplatin-etoposide plus durvalumab.; No control or comparator; observational description only.; No doses, treatment schedule, toxicity, or response metrics provided in the abstract.; Limited clinical detail (e.g., imaging, histology, biomarkers) provided in the abstract..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Human trialTrialReported negativeLimited evidenceTier 4 · clinicaln = 82
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
Gynecologic oncology · Feb 2023 · single-center, randomized, open-label, phase 2 study
This single-center randomized phase 2 study assigned 82 patients with recurrent or persistent endometrial cancer to durvalumab alone or durvalumab plus tremelimumab and measured overall response rate and 24-week PFS. The overall response rate was 10.8% in the durvalumab arm (n=37 evaluable) and 5.3% in the combination arm (n=38 evaluable); the pre-specified ORR efficacy thresholds were not met. Per protocol, 24-week PFS was not compared to historical controls and no new safety signals were reported. Most patients were MMR-proficient, and the authors conclude there was limited activity of single-agent and combined checkpoint blockade in this population.
Reported effects: enrolled 82, n=82 · evaluable_for_efficacy 75, n=75 · +4 more
Studied with: tremelimumab.
Key findings
- Eighty-two patients were enrolled; 77 were evaluable for toxicity (Arm 1: 38, Arm 2: 39) and 75 evaluable for efficacy (Arm 1: 37, Arm 2: 38).
- Patient were stratified by MMR status (Arm 1: 5, Arm 2: 4 were MMR-deficient).
- The ORR in Arm 1 was 10.8% (one-sided 90% CI: 4.8-100%); the ORR in Arm 2 was 5.3% (one-sided 90% CI: 1.4-100%).
- Since the primary endpoint of ORR was not met, 24-week PFS was not compared to historical controls per protocol specification.
- No new safety signals were identified.
Limitations: Single-center phase 2 trial; Relatively small overall sample size and small numbers evaluable per arm (37-38 evaluable for efficacy); Very small MMR-deficient subgroup (Arm 1: 5, Arm 2: 4), limiting assessment in that population; Open-label design; Primary endpoint (ORR) not met, and 24-week PFS was not formally compared to historical controls per protocol.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Durvalumab's evidence base, and anything that's been retracted.
Recently added- Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab Case report · added Jun 2026
- Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis Meta-analysis · added Jun 2026
- Managing a Rare Case of Mixed Extrapulmonary Small Cell Carcinoma and Adenocarcinoma of the Prostate Case report · added Jun 2026
- Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study Human trial · added Jun 2026
Cancers where Durvalumab reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Human evidence
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..
Cited positive studies (1)
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..
Cited positive studies (1)
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..
Cited positive studies (1)
Evidence at a glance: Durvalumab by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Includes human trial or meta-analysis evidence.
Largest credible effect: pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 PMID 38422895 · hazard ratios 0.34–0.87 across 6 studies
Most authoritative study: Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Findings conflict across studies.
Includes human trial or meta-analysis evidence.
Largest credible effect: pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 PMID 38422895 · hazard ratios 0.34–0.87 across 6 studies
Most authoritative study: Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Based on a single study.
Includes human trial or meta-analysis evidence.
Largest credible effect: ORR Arm 2 5.3% [1.4–100], p one-sided 90% CI, n=38 PMID 36512912 · effect sizes 4–82 across 4 studies
Most authoritative study: Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
Based on a single study.
Includes human trial or meta-analysis evidence.
Largest credible effect: ORR Arm 2 5.3% [1.4–100], p one-sided 90% CI, n=38 PMID 36512912 · effect sizes 4–82 across 4 studies
Most authoritative study: Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
Based on a single study.
Includes human trial or meta-analysis evidence.
Largest credible effect: pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 PMID 38422895 · hazard ratios 0.34–0.87 across 6 studies
Most authoritative study: Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis
Based on a single study.
No primary experimental studies yet.
Most authoritative study: Managing a Rare Case of Mixed Extrapulmonary Small Cell Carcinoma and Adenocarcinoma of the Prostate
No human studies yet · No numeric effect sizes reported · Based on a single study.
No primary experimental studies yet.
Largest credible effect: time_to_death_after_starting_chemoimmunotherapy 10 mo, n=1 PMID 40129783
Most authoritative study: Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab
No human studies yet · Based on a single study.
No primary experimental studies yet.
Most authoritative study: Managing a Rare Case of Mixed Extrapulmonary Small Cell Carcinoma and Adenocarcinoma of the Prostate
No human studies yet · No numeric effect sizes reported · Based on a single study.
No primary experimental studies yet.
Most authoritative study: Managing a Rare Case of Mixed Extrapulmonary Small Cell Carcinoma and Adenocarcinoma of the Prostate
No human studies yet · No numeric effect sizes reported · Based on a single study.
Dose: as studied, not a recommendation
These are doses as studied or reported, never a recommendation. The right amount of Durvalumab depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Doses reported in studies- Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study durvalumab 1500 mg; tremelimumab 75 mg every 4 weeks · Human trial · Feb 2023
Clinical trials studying Durvalumab
15 ongoing · 7 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.
Completed
- A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersPrimary outcome measured: Number of Subjects With Treatment-emergent Adverse Events (TEAEs)
- Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.Primary outcome measured: Dose Escalation Part: Establish the Recommended Phase II Dose (RP2D), the Maximum Tolerated Dose (MTD) Evaluated on the First Cycle (D1 to D21), the Safety Profile, and the Dose Limiting Toxicities (DLT) of Trabectedin Given in Combination With Durvalumab
- Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsNCT02658214Phase 1Completed Thu Nov 14tests Durvalumabtests Etoposidetests Carboplatintests Sodium butyratetests Paclitaxeltests Cisplatintests Gemcitabine
- Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon CancerPrimary outcome measured: Immune-related Best Overall Response Rate.
- First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
- Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma SubtypesPrimary outcome measured: Progression-Free Survival (PFS)
- A Study of Durvalumab With or Without Tremelimumab in Endometrial CancerPrimary outcome measured: Treatment Efficacy Determined by Measuring the Overall Response Rate
4 stopped (terminated / withdrawn / suspended)
- A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors · Terminated
- Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer · Terminated
- Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer · Terminated
- Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin · Terminated
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.